Exelixis
EXEL
#2109
Rank
NZ$12.18 B
Marketcap
$42.70
Share price
-1.53%
Change (1 day)
18.19%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of June 2024 : NZ$0.32 B

According to Exelixis's latest financial reports the company's total debt is NZ$0.32 B. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2024)

Total debt by year

Year Total debt Change
2023-12-31NZ$0.30 B0.28%
2022-12-31NZ$0.29 B300.08%
2021-12-31NZ$74.86 M9.69%
2020-12-31NZ$68.25 M-4.11%
2019-12-31NZ$71.17 M220.21%
2018-12-31NZ$22.22 M5.67%
2017-12-31NZ$21.03 M-92.3%
2016-12-31NZ$0.27 B-55.34%
2015-12-31NZ$0.61 B34.35%
2014-12-31NZ$0.45 B7.63%
2013-12-31NZ$0.42 B3.24%
2012-12-31NZ$0.40 B76.08%
2011-12-31NZ$0.23 B-14.27%
2010-12-31NZ$0.27 B145.68%
2009-12-31NZ$0.11 B-45.87%
2008-12-31NZ$0.20 B29.71%
2007-12-31NZ$0.15 B-8.93%
2006-12-31NZ$0.17 B-20.71%
2005-12-31NZ$0.21 B5.46%
2004-12-31NZ$0.20 B20.85%
2003-12-31NZ$0.17 B20.96%
2002-12-31NZ$0.14 B19.86%
2001-12-31NZ$0.11 B249.37%
2000-12-31NZ$33.73 M32.56%
1999-12-31NZ$25.44 M

Total debt for similar companies or competitors

Company Total debt differencediff. Country
NZ$34.65 B 10,725.89%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$41.15 B 12,757.84%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$61.07 B 18,983.21%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$87.29 B 27,172.41%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$101.25 B 31,536.17%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$67.06 B 20,853.25%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$111.00 B 34,582.38%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$5.75 M-98.20%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$62.52 M-80.47%๐Ÿ‡บ๐Ÿ‡ธ USA